UACC-812細(xì)胞

生長狀態(tài)： 貼壁生長

數(shù)量： 大量

年限： 43 years

運(yùn)輸方式： 凍存運(yùn)輸

ATCC Number： CRL-1897?

相關(guān)**： 導(dǎo)管癌

器官來源： **

細(xì)胞形態(tài)： 上皮樣

是否是腫瘤細(xì)胞： 1

物種來源： 人

Designations: UACC-812

Depositors: A Liebovitz, J Trent

UACC-812細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: mammary gland; breast

Disease: ductal carcinoma

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The breast carcinoma UACC-812 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona. The cells are distributed for research purposes only. The University of Arizona has released the line subject to the following: 1. UACC-812 or their products MUST NOT BE DISTRIBUTED to third parties. Commercial interests are the exclusive property of the University of Arizona. 2. UACC-812細(xì)胞Any proposed commercial use of these cells must first be negotiated with the Director of the Arizona Cancer Center, University of Arizona, 1501 N. Campbell Avenue, Tucson, Arizona 85724. Telephone (602) 626-7925, FAX (602) 626-2284. 3. In all papers reporting any use of these of these cells or derived products, a direct reference will be made to the original publication given above.

Isolation: Isolation date: 1986

Receptors: estrogen receptor

progesterone receptor

Cytogenetic Analysis: range = 58 to 64; abnormal banding region in 3p

Age: 43 years

Gender: female

Comments: This cell line was established by A. Liebovitz and associates in 1986 from breast tissue removed at mastectomy to remove a ductal carcinoma (stage II, grade IV).

Prior to surgery, the patient had received extensive chemotherapy.

The cells exhibit a 15 fold amplification of the HER-2/neu oncogene sequence.

UACC-812細(xì)胞They are negative for estrogen receptors, progesterone receptors and P glycoprotein.

Propagation: ATCC complete growth medium: Leibovitz's L-15 medium with 2 mM L-glutamine supplemented with 20 ng/ml human EGF and 20% fetal bovine serum

Atmosphere: air, 100%

Temperature: 37.0°C

Growth conditions: The cells grow very slowly, and growth is enhanced by using 20% fetal bovine serum and adding epidermal growth factor (20 ng/ml) to the medium.

Subculturing: Protocol:

Remove and discard culture medium.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: UACC-812細(xì)胞To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Add appropriate aliquots of the cell suspension to new culture vessels.

Incubate cultures at 37?C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Doubling Time: 100 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008

recommended serum:ATCC 30-2020

purified DNA:ATCC 45534

purified DNA:ATCC 45535

UACC-812細(xì)胞purified DNA:ATCC CRL-1897D

References: 22207: . . Proc. Am. Assoc. Cancer Res. 29: 24, 1988.

26165: Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877